Blood transcriptomic biomarkers of Alzheimer's disease patients treated with EHT 0202

Manuscript Number: 

12-1501R2

Author(s): 
Elodie Blondiaux, Jennifer Carriere, Laurent Desire, Richard Einstein, Pascale Fehlbaum-Beurdeley, Raphael Haddad, Matthew P. Pando, Olivier Sol, Weiyin Zhou

Disclosures

Elodie Blondiaux

  • Consulting Fees:
    I am employed by Effi-Stat, a contract research organisation, contracted by Exonhit (and other companies) for statistical services.

Jennifer Carriere

  • Consulting Fees:
    holds shares of Exonhit
    Equity:
    Stock options
    Sponsors:
    current employee of Exonhit

Laurent Desire

  • Equity:
    hold shares of Exonhit
    Sponsors:
    employee of Exonhit
    Patents/Royalties
    coinventor on patents related to EHT 0202

Richard Einstein

  • Equity:
    holds share
    Sponsors:
    former employee of Exonhit

Pascale Fehlbaum-Beurdeley

  • Equity:
    As an employee of Exonhit, I hold shares of Exonhit

Raphael Haddad

  • Equity:
    Raphael Haddad hold shares of Exonhit.
    Sponsors:
    Raphael Haddad was an employee of Exonhit.

Matthew P. Pando

  • Equity:
    Hold stock options in Exonhit
    Sponsors:
    Executive Vice President, Therapeutics at Exonhit and a member of the Management Board
    Patents/Royalties
    An inventor on multiple patents and provide scientific expertise in defending Exonhit's patent portfolio

Olivier Sol

  • Equity:
    owner of stock options from ExonHit
    Sponsors:
    employed at ExonHit as a Clinical Director and responsible for the clinical data mentionned in the paper

Weiyin Zhou

  • Equity:
    stock options
    Patents/Royalties
    patent